Регенерация органов и тканей · Jul 20, 2026

Effects of dihydroquercetin therapy on clinical status and senescent cell burden in with chronic heart failure (QUEST-CHF Study): Rationale and clinical trial protocol. Version 2.0

By Daudov IS, Efimenko AY, Akopyan ZA et al.

Persistent systemic inflammation is a critical component in the pathogenesis of age-associated diseases, particularly chronic heart failure (CHF). Numerous studies have demonstrated elevated inflammatory biomarkers in patients with CHF. One mechanism sustaining this chronic inflammation is the accumulation of senescent cells, which secrete a complex of bioactive factors known as the senescence-associated secretory phenotype (SASP). Senolytic therapy, which selectively eliminates senescent cells and reduces associated inflammation, represents a promising therapeutic approach for CHF. Dihydroquercetin, a compound with demonstrated senolytic activity in experimental models and a proven safety profile in clinical trials for other indications, was selected for the present study. Objective: to evaluate the effects of different doses of dihydroquercetin on senescent cell biomarkers and the clinical status of patients with CHF. Materials and methods. This is a randomized, comparative, double-blind clinical trial. The study will enroll 60 patients following an unplanned healthcare visit for symptoms and/or signs of congestion due to heart failure requiring hospitalization and/or intensification of diuretic therapy. Patients will be randomized in a 2:1 ratio (n = 40 in Group 1; n = 20 in Group 2) to receive either 100 mg/day or 30 mg/day of a liquid water-soluble form of dihydroquercetin (Taxifolin Aqua, “Advanced Technologies” LLC) as an adjunct to standard of care. Randomization will be performed using randomization tables, assuming group homogeneity across baseline parameters. Recruitment is scheduled over a 9-month period at a single study center. The follow-up period will be 16 weeks from enrollment. Follow-up visits are scheduled at 8 and 16 weeks to assess quality of life, functional status, and senescent cell burden biomarkers. Current status. Patient recruitment is currently ongoing.

doi.org/10.60043/2949-5938-2026-1-77-87Open accessInterventions

AgingResearch.News